Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralat...

متن کامل

Radioactive Estrogens in Tissues of Postmenopausal Women with Breast Neoplasms.

women with mammary carcinoma, the concentrations of total radioactive estrogen and the individual radiometabolites estradiol and estrone, and an uncharacterized fraction (Ep), were determined in several body tissues. Specimens of mammary tissue, mammary tumor, abdominal fat, muscle, and skin were removed 30 minutes after the infusion of the radioactive hormone. The median concentration of radio...

متن کامل

Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?

Background: The primary objective of this study was to assess BMD change in Iranian females with breast cancer. Methods: A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spin...

متن کامل

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole's long-term ...

متن کامل

Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.

PURPOSE To assess the predictive value of Ki67 expression in postmenopausal hormone receptor-positive early-breast cancer patients, who were either treated with adjuvant tamoxifen (TAM) alone or with TAM followed by anastrozole (ANA). EXPERIMENTAL DESIGN Expression of Ki67 was determined centrally by immunohistochemistry on whole tissue sections of postmenopausal endocrine-responsive breast c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cancer Prevention Research

سال: 2011

ISSN: 1940-6207,1940-6215

DOI: 10.1158/1940-6207.capr-11-0154